Similar results were reported by Yadav et al. who found that 25(OH)-VD supplementation reduced PTH, BAP and CTX in a randomized, double blind, placebo-controlled trial including 117 patients with CKD stage 3–4 [92]. The gene discussed is CYP27A1; the disease is chronic kidney disease.